Quality assessment of various brands of losartan potassium tablets sold in Uyo Metropolis
Keywords:
Angiotensin II receptor antagonist, AT1 receptor, Assay, losartan potassiumAbstract
Background: Losartan potassium is a non-peptide angiotensin II receptor antagonist with high affinity and
selectivity for the AT1 receptor, used for the management of hypertension, diabetic nephropathy as well as
hypertension with left ventricular hypertrophy. Various brands of Losartan potassium were assayed to reveal their
conformity with compendia requirements and assure that the brands are of acceptable standards for human
consumption.
Methods: Qualitative and quantitative analyses of ten (10) brands coded A-J of Losartan potassium sold in Uyo
metropolis were carried out using standard physical and ultraviolet (UV) spectrophotometric methods
respectively.
Results: All the brands tested met the official requirements for uniformity of weight. Brand I failed the
disintegration test by British Pharmacopeia specification (disintegration within15 mins.) but conformed to the
United States Pharmacopeia specification (disintegrated within 30 mins.). Only brand J complied with official
dissolution specification (>80% at 30 mins.) when 0.1 N HCl was used as the dissolution medium, whereas, all
the brands except brand F (<80%) complied when distilled water was used. The calibration curve for reference
Losartan potassium in methanol was linear over a concentration range of 0.00-50 µg/mL with correlation
coefficient of 0.985. All the brands passed the British Pharmacopoeia (BP) and United States Pharmacopoeia
(USP) requirements for percentage drug content of 98.5% to 101.5% and 95.0% to 105.0% respectively.
Conclusion: The brands performed creditably well in their physical characteristics and percentage recoveries. The
assay method in this study was simple, inexpensive, and reproducible and can be routinely used to assay Losartan
potassium tablets.
References
Al-Majed ARA, Assiri E, Khalil NY, Abdel-Aziz HA. Losartan: comprehensive profile. Profiles of Drug
Substances, Excipients and Related Methodology 2015; 40:159-194.
Andersen S, Rossing P, Juhl TR, Deinum J, Parving, HH. (). Optimal dose of losartan for renoprotection in
diabetic nephropathy. Nephrology Dialysis Transplantation 2002; 17(8):1413-1418.
Gao, J., Wang, X., Song, W., Wang, Y. and Xiao, Y. Dysglycemia and Dyslipidemia Models in Nonhuman
Primates: Part V. Diabetic Nephropathy and Effects of Angiotensin Ⅱ Receptor 06, 2022.
Bartko PE, Dal-Bianco JP, Antagonist Losartan. 2022 Journal of Diabetes and Metabolism (Open Access).
Retrieved, April Guerrero JL, Beaudoin J, Szymanski C, Kim DH, Seybolt MM, Handschumacher MD, Sullivan
S, Garcia ML, Titus JS. Effect of losartan on mitral valve changes after myocardial infarction. Journal of the
American College of Cardiology 2017; 70(10):1232-1244.
AAFP. Losartan Does More Than Lower Blood Pressure. American Family Physician 2002; 66(5):865-866.
Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A,
Sugisaki T, Suzuki H, Umemura S, Kawaguchii Y, Uchida S, Kuwahara M, Yamazaki T. Renoprotective effect
of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the
Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients JLIGHT),
Hypertens Res 2004; 27(1):21-30.
Hameed A, Naveed S, Abbas S, Qamar F. Pharmaceutical equivalent study of losartan potassium formulation
available in Karachi, Pakistan. Journal of Bioequivalence and Bioavailability 2016; 8(6):283-284.
Lam M, Beqo A, Thumar R. Overcoming Cough and Angioedema: Advocating for the Use of ARBs over
ACE Inhibitors. Annals of Pharmacotherapy, https://doi.org/10.1177/10600280211029952. Retrieved, April 10,
Igboasoiyi AC, Offor AC, Egeolu AP. Quality Assessment of various Brands of Ciprofloxacin Hydrochloride
Tablets sold in Uyo metropolis, Nigerian Journal of Pharmaceutical and Applied Science Research 2018;
(2):89-93.
Ubajaka CF, Obi-Okaro AC, Emelumadu OF, Azumarah MN, Ukegbu AU, Ilikannu SO. Factors
Associated with Drug Counterfeit in Nigeria: A Twelve Year Review. British Journal of Medicine & Medical
Research 2016; 12(4):1-8. Article no.BJMMR.21342 ISSN: 2231-0614, NLM ID: 101570965
SCIENCEDOMAIN international www.sciencedomain.org
Adegbolagun OA, Olalade OA, Osumah SE. Comparative evaluation of the biopharmaceutical and chemical
equivalence of some commercially available brands of lisinopril hydrochloride tablets. Tropical Journal of
Pharmaceutical Research, 2007; 6:737-745.
British Pharmacopoeia (2013). Safety data sheet. Article 31: version number 2, London 2013. 4p [13]
United States Food and Drug Administration, Center for Drug Evaluation and Research Guidance for Industry:
Dissolution testing of immediate release solid oral dosage forms, 1997; available at:
http://www.fda.gov/cder/Guidance/1713bp1.pdf
United States Pharmacopoeia and National Formulary USP-24 NF-19 (2014). The United States
Pharmacopoeia Convention Inc. Rockville, M.D., 2014.1890-1891pp
Sultana MM. Performance Evaluation of Losartan Potassium Tablets of five different Pharmaceutical
Companies in Bangladesh, Daffodil International University Library. Daffodil 2017. 22-23pp
British Pharmacopoeia. British Pharmacopeia. Her Majesty Stationary Press, London 2009. 1163p
Jantratid E, Janssen N, Reppas C, Dressma J. Dissolution Media Simulation Conditions in the Proximal
Human Gastrointestinal Tract: AnUpdate. Pharmaceutical Resources 2008. 25:1663-1676.
Guidance for Industry: Immediate Release Solid oral Dosage Forms, Scale-Up and Post Approval Changes:
Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence
Documentation. Rockville, MD, USA, US Food and Drug Administration, 1995.
British Pharmacopoeia. Medicines and Health Product Regulatory Agency, Volume II, London 2015. 136p
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Journal of Drug Discovery and Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
